Recently, Yao et al. [35] reported on broader biological characteristics in initially diagnosed DLBCL patients, revealing that conBMI also shows an enrichment for unfavorable markers such as CD5 expression [38] and MYC gene rearrangement [39]. The gene discussed is MYC; the disease is diffuse large B-cell lymphoma.